Influenza vaccination coverage and related factors among Spanish patients with chronic obstructive pulmonary disease.

Vaccine

Unidad de Docencia e Investigación en Medicina Preventiva y Salud Pública, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Avda de Atenas s/n, Alcorcón 28402, Spain.

Published: May 2005

This study sought: to describe influenza vaccination coverages among COPD patients treated in a primary-care setting; and to analyse the factors linked to compliance with vaccination recommendations. This was a descriptive study in a primary-care (PC) setting. Each of the 2422 randomly selected medical practitioners included in the study was required to recruit five COPD patients. Information was drawn from patients' clinical histories and personal interviews. As the dependent variable, we took the answer (yes or no) to the question, "did you have an influenza vaccination in the most recent campaign?"; and as independent variables, we analysed socio-demographic data, health-status related variables, lifestyles and history of pneumococcal vaccination. A total of 10,711 patients were enrolled 87.2% reported having been vaccinated in the most recent campaign. In conclusion, Spanish COPD patients treated in a primary-care setting can be said to enjoy good vaccine coverages against the influenza virus. More frequent contact with the general practitioner and a history of pneumococcal vaccination increase the likelihood of being vaccinated considerably, and measures should be implemented with the aim of improving coverages among younger subjects and those who lead less healthy lifestyles.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2005.02.007DOI Listing

Publication Analysis

Top Keywords

influenza vaccination
12
copd patients
12
primary-care setting
12
patients treated
8
treated primary-care
8
history pneumococcal
8
pneumococcal vaccination
8
patients
5
vaccination
5
influenza
4

Similar Publications

Introduction: Vaccines to prevent important infections involving, e.g. influenza viruses, severe acute respiratory syndrome-causing coronaviruses (e.

View Article and Find Full Text PDF

Idiopathic inflammatory myopathies (IIM), or myositis, are a heterogeneous group of autoimmune disorders that can affect multiple organs, including the muscles, skin, joints, lungs, heart, and gastrointestinal tract. While new-onset myositis has been reported following SARS-CoV-2 infection, cases associated with COVID-19 vaccination remain rare. We describe a unique case of severe progressive edematous facial myositis resembling angioedema in a 22-year-old man, with onset one to two weeks after receiving dual SARS-CoV-2 and influenza vaccinations.

View Article and Find Full Text PDF

Purpose: In patients with end-stage renal disease (ESRD), infections, particularly pneumonias, are the most common cause of hospital admissions and death after cardiovascular diseases. It is recommended that dialysis patients receive the pneumococcal vaccine every five years and the influenza vaccine annually. Our study aims to determine the awareness and factors affecting influenza and pneumococcal vaccination rates in hemodialysis patients.

View Article and Find Full Text PDF

Distinct evolution patterns of influenza viruses and implications for vaccine development.

Innovation (Camb)

January 2025

School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong (HKU), Hong Kong SAR, China.

In conclusion, the distinct evolution patterns of panzootic influenza A(H5Nx) compared to A(H1N1) and A(H3N2) complicate vaccine development. Effective strategies must consider these unique patterns and the impact of pre-existing immunity. Leveraging AI-based methods for optimized antigen design is essential to mitigate the potential impact of emerging antigenically variable strains and will provide valuable insights for developing more effective vaccines to prepare for future pandemics.

View Article and Find Full Text PDF

Rethinking Optimal Immunogens to Face SARS-CoV-2 Evolution Through Vaccination.

Influenza Other Respir Viruses

January 2025

Área de Investigación en Vacunas, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Valencia, Spain.

SARS-CoV-2, which originated in China in late 2019, quickly fueled the global COVID-19 pandemic, profoundly impacting health and the economy worldwide. A series of vaccines, mostly based on the full SARS-CoV-2 Spike protein, were rapidly developed, showing excellent humoral and cellular responses and high efficacy against both symptomatic infection and severe disease. However, viral evolution and the waning humoral neutralizing responses strongly challenged vaccine long term effectiveness, mainly against symptomatic infection, making necessary a strategy of repeated and updated booster shots.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!